Table 7.

Select protocol performance outcome comparisons (phase II and III combined)

Mean Duration Days and Mean Percents	Oncology	Non-Oncology	Rare Diseases	Non-Rare Diseases
Total Clinical Trial Duration (Final Protocol to DBL)	1,598.7	1,080.9	1,304.8	1,147.4
Study Initiation Duration (Final Protocol to FPFV)	148.4	146.4	173.3	141.2
Enrollment Duration (FPFV-LPFV)	575.2	436.8	603.2	444.2
Study Conduct Duration (LPFV-LPLV)	659.4	334.7	384.1	384.8
Treatment Duration (FPFV-LPLV)	1,327.2	852.0	1,073.6	905.9
Study Close-Out Duration (LPLV-DBL)	68.5	59.9	61.4	61.4
Time to Clinical Report (DBL-CSR)	186.7	154.1	142.5	161.8
Randomization Rate	67.1%	70.9%	76.3%	68.9%
Completion Rate	31.4%	80.0%	50.8%	72.5%